Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses | Zendy

Xuexue Xiao | Zendy; Su Jin | Zendy; Geling Zhangyang | Zendy; Shiwei Xiao | Zendy; Na Fang | Zendy; Junqiu Yue | Zendy

Open Access

Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses

Author(s) -

Xuexue Xiao,

Su Jin,

Geling Zhangyang,

Shiwei Xiao,

Na Fang,

Junqiu Yue

Publication year - 2022

Publication title -

gland surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.643

H-Index - 22

eISSN - 2227-8575

pISSN - 2227-684X

DOI - 10.21037/gs-22-248

Subject(s) - medicine , immunohistochemistry , apocrine , breast cancer , breast carcinoma , tumor infiltrating lymphocytes , oncology , trastuzumab , triple negative breast cancer , cancer , carcinoma , pathology , immunotherapy

Pure apocrine carcinoma (AC) of the breast can be divided into human epidermal growth factor receptor-2 (HER2)-positive and triple-negative apocrine carcinoma (TNAC). Some studies showed that triple negative breast cancer with low tumor-infiltrating lymphocytes (TILs) and high programmed death-ligand 1 (PD-L1) status may be a therapeutic target for immune checkpoint inhibitors. However, the clinicopathological features of different HER2 expression, TILs status and PD-L1 expression in AC are not clear. Therefore, we investigate the status of TILs and PD-L1, as well as the clinicopathological features of pure apocrine carcinoma of the breast.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research